Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique
Author:
- A.-J. ScheenASA.-J. Scheen
- 1 March 2015
- journal article
- Published by Elsevier in Médecine des Maladies Métaboliques
- Vol. 9 (2) , 186-197
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Metformin: From Mechanisms of Action to TherapiesCell Metabolism, 2014
- Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisalDiabetes & Metabolism, 2014
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesThe Lancet, 2014
- Do not forget that type 2 diabetes does not only expose to cardiovascular complicationsDiabetes & Metabolism, 2014
- Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence?Diabetes & Metabolism, 2014
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetesDiabetes & Metabolism, 2013
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998